8 News & Press Releases found
GI Innovation News
-
GI Innovation submits a preliminary application for KOSDAQ listing…Unicorn IPO ready to launch
Aim for IPO, in the 4Q of 2022 through Unicorn special track Clinical trial data from the phase 1/2 study of GI-101 monotherapy and combination therapy with Keytruda of GI-101 and phase 1 study of GI-301 to be released by end of 2022 GI ...
-
GI Innovation·GI Cell·Yonsei University Health System, Signed MoU to establish a cell therapy center for advanced biopharmaceutical
-GI Innovation·GI Cell, respectively establishing a cell therapy center at Severance Hospital·Songdo Severance Hospital(tentative named) -Establishment of the seamless process for research, production, clinical trials, Regulatory ...
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer ...
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment ...
-
GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy
GI Innovation, Inc., (CEO, Jun Ho Hong) announced that GI Innovation signed a clinical supply collaboration agreement with global biopharmaceutical company AstraZeneca for development of GI-101 and Imfinzi® combination therapy. Under this ...
-
GI Innovation signed a contract with Medirama for joint research development of next generation innovative immuno-oncology
-GI Innovation-Medirama forms a ‘Joint Development Committee’ for professionalism maximization -Joint development for two new immuno-oncology… partial shared cooperative model of commercialization revenue GI Innovation, an ...
-
GI Innovation sings MoU for a new biopharmaceutical development with Merck
-Accelerating for development of high expression cell line through combination of GI-SMARTTM platform technology of GI Innovation and CHOZN® Platform of Merck -Expecting synergy of both companies for biopharmaceutical ...
-
GI Innovation released passing of early clinical research of GI-101 in SITC, U.S.A
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence ...